Satellos Bioscience (NASDAQ:MSLE) Announces Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Satellos Bioscience (NASDAQ:MSLE) issued its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18), Zacks reports.

Satellos Bioscience Price Performance

Shares of MSLE traded down $0.21 on Friday, reaching $9.61. 38,447 shares of the company’s stock were exchanged, compared to its average volume of 48,356. The stock’s 50 day simple moving average is $8.21. Satellos Bioscience has a 12 month low of $4.84 and a 12 month high of $13.39. The stock has a market cap of $200.25 million, a PE ratio of -5.00 and a beta of 1.51.

Wall Street Analyst Weigh In

MSLE has been the topic of a number of research analyst reports. Guggenheim initiated coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price target on the stock. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright increased their price target on shares of Satellos Bioscience from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a research report on Thursday, May 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.75.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.